Optimization of SARS-CoV-2 culture from clinical samples for clinical trial applications
mSphere · 21.11.2024 · 9 (11)
DOI: 10.1128/msphere.00304-24 ↗Kurz gefasst
Fachartikel in der Zeitschrift mSphere, erschienen am 21.11.2024. Verfasst von Dominic Wooding und 22 weiteren Autor:innen. Beteiligte Einrichtung: Centre for Drugs and Diagnostics, Liverpool School of Tropical Medicine and Hygiene, Liverpool, United Kingdom. Hauptthemen laut MEDLINE: SARS-CoV-2, COVID-19, Viral Load, Virus Replication. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Wellcome Trust, Medical Research Council.
Abstract (Originalsprache)
Clinical trials of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) therapeutics often include virological secondary endpoints to compare viral clearance and viral load reduction between treatment and placebo arms. This is typically achieved using quantitative reverse-transcriptase PCR (RT-qPCR), which cannot differentiate replicant competent virus from non-viable virus or free RNA, limiting its utility as an endpoint. Culture-based methods for SARS-CoV-2 exist; however, these are often insensitive and poorly standardized for use as clinical trial endpoints. We report optimization of a culture-based approach evaluating three cell lines, three detection methods, and key culture parameters. We show that Vero-angiotensin-converting enzyme 2-transmembrane serine protease 2 cells in combination with RT-qPCR of culture supernatants from the first passage provides the greatest overall detection of Delta viral replication (22 of 32, 68.8%), being able to identify viable virus in 83.3% (20 of 24) of clinical samples with initial Ct values of
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Centre for Drugs and Diagnostics, Liverpool School of Tropical Medicine and Hygiene, Liverpool, United Kingdom.
- Department of Clinical Sciences, Liverpool School of Tropical Medicine and Hygiene, Liverpool, United Kingdom.
- Manchester University NHS Foundation Trust, Research and Innovation, Manchester, United Kingdom.
- Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, United Kingdom.
- Research and Evaluation, UK Health Security Agency, Porton Down, Salisbury, United Kingdom.
- University of Liverpool, Liverpool, United Kingdom.
ORCID-Profile: Alessandra Romero-Ramirez, Rachel L Byrne, Ana Cubas-Atienzar, Thomas Edwards
Förderung
- Wellcome Trust
- Medical Research Council
Zitieren
APA
Wooding, D., Buist, K., Romero-Ramirez, A., Savage, H., Watkins, R., Bengey, D., Greenland-Bews, C., Thompson, C. R., Kontogianni, N., Body, R., Hayward, G., Byrne, R. L., Gould, S., CONDOR Steering Group, Myerscough, C., Atkinson, B., Shaw, V., Greenhalf, B., Adams, E., …, & Edwards, T. (2024). Optimization of SARS-CoV-2 culture from clinical samples for clinical trial applications. mSphere, 9(11). https://doi.org/10.1128/msphere.00304-24
Vancouver
Wooding D, Buist K, Romero-Ramirez A, Savage H, Watkins R, Bengey D, et al. Optimization of SARS-CoV-2 culture from clinical samples for clinical trial applications. mSphere. 2024;9(11). doi:10.1128/msphere.00304-24
BibTeX
@article{Wooding2024,
author = {Wooding, Dominic and Buist, Kate and Romero-Ramirez, Alessandra and Savage, Helen and Watkins, Rachel and Bengey, Daisy and Greenland-Bews, Caitlin and Thompson, Caitlin R and Kontogianni, Nadia and Body, Richard and Hayward, Gail and Byrne, Rachel L and Gould, Susan and CONDOR Steering Group, CONDOR Steering Group and Myerscough, Christopher and Atkinson, Barry and Shaw, Victoria and Greenhalf, Bill and Adams, Emily and Cubas-Atienzar, Ana and Khoo, Saye and Fletcher, Tom and Edwards, Thomas},
title = {Optimization of SARS-CoV-2 culture from clinical samples for clinical trial applications},
journal = {mSphere},
year = {2024},
volume = {9},
number = {11},
doi = {10.1128/msphere.00304-24}
}
EUVIMED